View in EDS

Phase II Study of Copanlisib in Patients With Tumors With PIK3CA Mutations: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1F.

Saved in:
Bibliographic Details
Title: Phase II Study of Copanlisib in Patients With Tumors With PIK3CA Mutations: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1F.
Authors: Damodaran S; The University of Texas MD Anderson Cancer Center, Houston, TX., Zhao F; Dana-Farber Cancer Institute-ECOG-ACRIN Biostatistics Center, Boston, MA., Deming DA; University of Wisconsin Carbone Cancer Center, Madison, WI., Mitchell EP; Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA., Wright JJ; Investigational Drug Branch, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD., Gray RJ; Dana-Farber Cancer Institute-ECOG-ACRIN Biostatistics Center, Boston, MA., Wang V; Dana-Farber Cancer Institute-ECOG-ACRIN Biostatistics Center, Boston, MA., McShane LM; Biometric Research Branch, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD., Rubinstein LV; Biometric Research Branch, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD., Patton DR; National Cancer Institute/Center for Biomedical Informatics & Information Technology, Rockville, MD., Williams PM; Molecular Characterization Laboratory, Frederick National Laboratory for Cancer Research, Frederick, MD., Hamilton SR; City of Hope Comprehensive Cancer Center, Duarte, CA., Suga JM; Kaiser Permanente, Vallejo, CA., Conley BA; Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD., Arteaga CL; UT Southwestern Medical Center, Dallas, TX., Harris LN; Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD., O'Dwyer PJ; University of Pennsylvania Abramson Cancer Center, Division of Medical Oncology, Philadelphia, PA., Chen AP; Developmental Therapeutics Clinic/Early Clinical Trials Development Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD., Flaherty KT; Dana-Farber Cancer Institute/Harvard Medical School/Massachusetts General Hospital, Boston, MA.
Source: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2022 May 10; Vol. 40 (14), pp. 1552-1561. Date of Electronic Publication: 2022 Feb 08.
Publication Type: Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural; Adaptive Clinical Trial
Journal Info: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1527-7755 (Electronic) Linking ISSN: 0732183X NLM ISO Abbreviation: J Clin Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 35133871
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Phase II Study of Copanlisib in Patients With Tumors With PIK3CA Mutations: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1F.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Damodaran+S%22">Damodaran S</searchLink>; The University of Texas MD Anderson Cancer Center, Houston, TX.<br /><searchLink fieldCode="AU" term="%22Zhao+F%22">Zhao F</searchLink>; Dana-Farber Cancer Institute-ECOG-ACRIN Biostatistics Center, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Deming+DA%22">Deming DA</searchLink>; University of Wisconsin Carbone Cancer Center, Madison, WI.<br /><searchLink fieldCode="AU" term="%22Mitchell+EP%22">Mitchell EP</searchLink>; Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA.<br /><searchLink fieldCode="AU" term="%22Wright+JJ%22">Wright JJ</searchLink>; Investigational Drug Branch, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.<br /><searchLink fieldCode="AU" term="%22Gray+RJ%22">Gray RJ</searchLink>; Dana-Farber Cancer Institute-ECOG-ACRIN Biostatistics Center, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Wang+V%22">Wang V</searchLink>; Dana-Farber Cancer Institute-ECOG-ACRIN Biostatistics Center, Boston, MA.<br /><searchLink fieldCode="AU" term="%22McShane+LM%22">McShane LM</searchLink>; Biometric Research Branch, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.<br /><searchLink fieldCode="AU" term="%22Rubinstein+LV%22">Rubinstein LV</searchLink>; Biometric Research Branch, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.<br /><searchLink fieldCode="AU" term="%22Patton+DR%22">Patton DR</searchLink>; National Cancer Institute/Center for Biomedical Informatics & Information Technology, Rockville, MD.<br /><searchLink fieldCode="AU" term="%22Williams+PM%22">Williams PM</searchLink>; Molecular Characterization Laboratory, Frederick National Laboratory for Cancer Research, Frederick, MD.<br /><searchLink fieldCode="AU" term="%22Hamilton+SR%22">Hamilton SR</searchLink>; City of Hope Comprehensive Cancer Center, Duarte, CA.<br /><searchLink fieldCode="AU" term="%22Suga+JM%22">Suga JM</searchLink>; Kaiser Permanente, Vallejo, CA.<br /><searchLink fieldCode="AU" term="%22Conley+BA%22">Conley BA</searchLink>; Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.<br /><searchLink fieldCode="AU" term="%22Arteaga+CL%22">Arteaga CL</searchLink>; UT Southwestern Medical Center, Dallas, TX.<br /><searchLink fieldCode="AU" term="%22Harris+LN%22">Harris LN</searchLink>; Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.<br /><searchLink fieldCode="AU" term="%22O'Dwyer+PJ%22">O'Dwyer PJ</searchLink>; University of Pennsylvania Abramson Cancer Center, Division of Medical Oncology, Philadelphia, PA.<br /><searchLink fieldCode="AU" term="%22Chen+AP%22">Chen AP</searchLink>; Developmental Therapeutics Clinic/Early Clinical Trials Development Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.<br /><searchLink fieldCode="AU" term="%22Flaherty+KT%22">Flaherty KT</searchLink>; Dana-Farber Cancer Institute/Harvard Medical School/Massachusetts General Hospital, Boston, MA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%228309333%22">Journal of clinical oncology : official journal of the American Society of Clinical Oncology</searchLink> [J Clin Oncol] 2022 May 10; Vol. 40 (14), pp. 1552-1561. <i>Date of Electronic Publication: </i>2022 Feb 08.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural; Adaptive Clinical Trial
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22American+Society+of+Clinical+Oncology%22">American Society of Clinical Oncology </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>8309333 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1527-7755 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%220732183X%22">0732183X </searchLink><i>NLM ISO Abbreviation: </i>J Clin Oncol <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=35133871
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1200/JCO.21.01648
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1552
    Titles:
      – TitleFull: Phase II Study of Copanlisib in Patients With Tumors With PIK3CA Mutations: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1F.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Damodaran S
      – PersonEntity:
          Name:
            NameFull: Zhao F
      – PersonEntity:
          Name:
            NameFull: Deming DA
      – PersonEntity:
          Name:
            NameFull: Mitchell EP
      – PersonEntity:
          Name:
            NameFull: Wright JJ
      – PersonEntity:
          Name:
            NameFull: Gray RJ
      – PersonEntity:
          Name:
            NameFull: Wang V
      – PersonEntity:
          Name:
            NameFull: McShane LM
      – PersonEntity:
          Name:
            NameFull: Rubinstein LV
      – PersonEntity:
          Name:
            NameFull: Patton DR
      – PersonEntity:
          Name:
            NameFull: Williams PM
      – PersonEntity:
          Name:
            NameFull: Hamilton SR
      – PersonEntity:
          Name:
            NameFull: Suga JM
      – PersonEntity:
          Name:
            NameFull: Conley BA
      – PersonEntity:
          Name:
            NameFull: Arteaga CL
      – PersonEntity:
          Name:
            NameFull: Harris LN
      – PersonEntity:
          Name:
            NameFull: O'Dwyer PJ
      – PersonEntity:
          Name:
            NameFull: Chen AP
      – PersonEntity:
          Name:
            NameFull: Flaherty KT
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 10
              M: 05
              Text: 2022 May 10
              Type: published
              Y: 2022
          Identifiers:
            – Type: issn-electronic
              Value: 1527-7755
          Numbering:
            – Type: volume
              Value: 40
            – Type: issue
              Value: 14
          Titles:
            – TitleFull: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
              Type: main
ResultId 1